Mitigation of doxorubicin-induced cardiotoxicity with an H(2)O(2)-Activated, H(2)S-Donating hybrid prodrug

Doxorubicin (DOX) is one of the most effective anticancer agents in clinical oncology. Its continued use, however, is severely limited by its dose-dependent cardiotoxicity which stems, in part, from its overproduction of reactive oxygen species (ROS) and often manifests itself as full-blown cardiomy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiwei, Yammani, Rama D., Brown-Harding, Heather, Soto-Pantoja, David R., Poole, Leslie B., Lukesh, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126844/
https://www.ncbi.nlm.nih.gov/pubmed/35609400
http://dx.doi.org/10.1016/j.redox.2022.102338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126844/
https://www.ncbi.nlm.nih.gov/pubmed/35609400
http://dx.doi.org/10.1016/j.redox.2022.102338

Ejemplares similares